Is Anixa Biosciences Inc (ANIX) Halal?
Shariah Screening — 5 Standards
Based on financial data from October 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 16.0% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 16.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.3% / 33% | 94.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 16.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.3% / 33% | 94.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -68.1% | |
| Return on Assets (ROA) | -40.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $204,000 |
| Debt-to-Equity | 1.4 |
| Current Ratio | 12.2 |
| Total Assets | $16M |
Price & Trading
| Last Close | $2.63 |
| 50-Day MA | $2.92 |
| 200-Day MA | $3.42 |
| Avg Volume | 165K |
| Beta | 0.5 |
|
52-Week Range
$2.33
| |
About Anixa Biosciences Inc (ANIX)
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Anixa Biosciences Inc (ANIX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Anixa Biosciences Inc is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Anixa Biosciences Inc's debt ratio?
Anixa Biosciences Inc's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.3%.
What are Anixa Biosciences Inc's key financial metrics?
Anixa Biosciences Inc has a market capitalization of $85M. Return on equity stands at -68.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.